Related Experiment Video
Updated: Jul 9, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Novel therapies for metastatic prostate cancer
Albert Jang1, Sree M Lanka2, Hui Ting Ruan3
1Division of Solid Tumor Oncology, Department of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, OH, USA.
Introduction:
Patients with metastatic prostate cancer, especially in the castrate-resistant setting, have a poor prognosis. Many agents have been approved for metastatic prostate cancer, such as androgen receptor pathway inhibitors, taxane-based chemotherapy, radiopharmaceuticals, and immunotherapy. However, prostate cancer remains the leading cause of cancer deaths in nonsmoking men. Fortunately, many more novel agents are under investigation.
Areas Covered:
We provide an overview of the broad group of novel therapies for metastatic prostate cancer, with an emphasis on active and recruiting clinical trials that have been recently published and/or presented at national or international meetings.
Expert Opinion:
The future for patients with metastatic prostate cancer is promising, with further development of novel therapies such as radiopharmaceuticals. Based on a growing understanding of prostate cancer biology, novel agents are being designed to overcome resistance to approved therapies. There are many trials using novel agents either as monotherapy or in combination with already approved agents with potential to further improve outcomes for men with advanced prostate cancer.
Insights
Novel therapies offer hope for metastatic prostate cancer patients, particularly in the castrate-resistant stage. Ongoing clinical trials are investigating new agents to improve outcomes for advanced prostate cancer.
Area of Science:
- Oncology
- Urology
- Medical Science
Background:
- Metastatic prostate cancer, especially castrate-resistant, has a poor prognosis.
- Despite approved treatments like androgen receptor pathway inhibitors, chemotherapy, radiopharmaceuticals, and immunotherapy, prostate cancer remains a leading cause of cancer death.
- Numerous novel therapeutic agents are currently under investigation.
Purpose of the Study:
- To provide an overview of novel therapies for metastatic prostate cancer.
- To highlight active and recruiting clinical trials for these novel agents.
- To summarize recent publications and presentations on advanced prostate cancer treatments.
Main Methods:
- Literature review of recent publications.
- Analysis of presented data from national and international meetings.
- Focus on active and recruiting clinical trials for novel metastatic prostate cancer therapies.
Main Results:
- The field of metastatic prostate cancer treatment is rapidly evolving with novel agents.
- Radiopharmaceuticals are a key area of development in novel prostate cancer therapies.
- Understanding of prostate cancer biology is driving the design of agents to overcome treatment resistance.
Conclusions:
- The future for metastatic prostate cancer patients is promising due to novel therapy development.
- New agents are being designed to combat resistance to existing treatments.
- Combination therapies and monotherapies in clinical trials show potential to improve outcomes for advanced prostate cancer.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...